BL LATANOPROST 50 MCG — DIN 02404052
LATANOPROST : 50 MCG · BAUSCH & LOMB INC · SOLUTION · wholesale supply in Canada
Health Canada status: CANCELLED PRE MARKET
What is BL LATANOPROST?
BL LATANOPROST 50 MCG contains LATANOPROST : 50 MCG. It is listed in the Health Canada Drug Product Database under DIN 02404052, held by BAUSCH & LOMB INC, supplied as SOLUTION for OPHTHALMIC administration. Health Canada currently lists it as cancelled pre market, status dated 17-Dec-2024. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
How much does Latanoprost cost around the world?
Latanoprost is listed on 19 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Italy | prezzo al pubblico (classe A) | 18 | 28 | EUR███.██ |
| Spain | PVP con IVA (public price) | 20 | 24 | EUR███.██ |
| Sweden | AIP (pharmacy purchase price) | 11 | 23 | SEK███.██ |
| Australia | ex-manufacturer | 7 | 21 | AUD███.██ |
| Czechia | max producer price (ex-factory) | 11 | 20 | CZK███.██ |
| Norway | max AUP (pharmacy retail) | 8 | 18 | NOK███.██ |
| Slovakia | categorised final price | 7 | 13 | EUR███.██ |
| Austria | KVP (Kassenverkaufspreis) | 10 | 10 | EUR███.██ |
| Greece | producer price (ex-factory) | 10 | 10 | EUR███.██ |
| United States | acquisition | 1 | 10 | USD███.██ |
| South Africa | single exit price | 9 | 9 | ZAR███.██ |
| Luxembourg | reimbursement | 8 | 8 | EUR███.██ |
| Bahrain | retail (max) | 7 | 7 | BHD███.██ |
| United Arab Emirates | public | 6 | 6 | AED███.██ |
| Hungary | producer price (ex-factory) | 6 | 6 | HUF███.██ |
| Romania | max producer price | 5 | 6 | RON███.██ |
| Saudi Arabia | public | 6 | 6 | SAR███.██ |
| United Kingdom | hospital | 2 | 2 | GBP███.██ |
| Morocco | PPV (public price) | 1 | 1 | MAD███.██ |
228 pack listings across 153 brand entries and 17 price bases, refreshed 08 Sep 2026. Ranges span every Latanoprost pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Latanoprost in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
16 holders have a Canadian DIN containing Latanoprost, across 19 DINs, of which 10 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| LABORATOIRE RIVA INC. | 2 | 1 | LATANOPROST, RIVA-LATANOPROST | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 2 | 1 | LATANOPROST OPHTHALMIC SOLUTION, SANDOZ LATANOPROST | Sourceable in Canada |
| ANGITA PHARMA INC. | 1 | 1 | AG-LATANOPROST | Sourceable in Canada |
| APOTEX INC | 1 | 1 | APO-LATANOPROST | Sourceable in Canada |
| BGP PHARMA ULC | 1 | 1 | XALATAN | Sourceable in Canada |
| GENERIC MEDICAL PARTNERS INC | 1 | 1 | MED-LATANOPROST | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 1 | 1 | JAMP LATANOPROST | Sourceable in Canada |
| LABORATOIRES THEA | 1 | 1 | MONOPROST | Sourceable in Canada |
| MANTRA PHARMA INC | 1 | 1 | M-LATANOPROST | Sourceable in Canada |
| MYLAN PHARMACEUTICALS ULC | 1 | 1 | MYLAN-LATANOPROST | Sourceable in Canada |
| TEVA CANADA LIMITED | 2 | 0 | TEVA-LATANOPROST | No marketed DIN |
| MINT PHARMACEUTICALS INC | 1 | 0 | MINT-LATANOPROST | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 50 MCG |
|---|---|
| Dosage form | SOLUTION |
| Route | OPHTHALMIC |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Latanoprost |
|---|---|
| ATC code | S01EE01 |
| AHFS class | 52:40.28 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02404052 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2404052 |
| Brand name | BL LATANOPROST |
| Generic / active ingredient | LATANOPROST : 50 MCG |
| Market authorization holder | BAUSCH & LOMB INC |
| Health Canada schedule | Prescription |
| ATC code | S01EE01 |
| ATC anatomical main group | S — Sensory organs |
| ATC therapeutic subgroup | S01EE |
| Current status | CANCELLED PRE MARKET |
| Status date | 17-Dec-2024 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
10 of 19 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-LATANOPROST | 50 MCG | SOLUTION | ANGITA PHARMA INC. | MARKETED | 02534835 |
| APO-LATANOPROST | 50 MCG | SOLUTION | APOTEX INC | MARKETED | 02296527 |
| JAMP LATANOPROST | 50 MCG | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | 02453355 |
| M-LATANOPROST | 50 MCG | SOLUTION | MANTRA PHARMA INC | MARKETED | 02513285 |
| MED-LATANOPROST | 50 MCG | SOLUTION | GENERIC MEDICAL PARTNERS INC | MARKETED | 02426935 |
| MONOPROST | 50 MCG | SOLUTION | LABORATOIRES THEA | MARKETED | 02456230 |
| MYLAN-LATANOPROST | 50 MCG | SOLUTION | MYLAN PHARMACEUTICALS ULC | MARKETED | 02373041 |
| RIVA-LATANOPROST | 50 MCG | SOLUTION | LABORATOIRE RIVA INC. | MARKETED | 02341085 |
| SANDOZ LATANOPROST | 50 MCG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 02367335 |
| XALATAN | 50 MCG | SOLUTION | BGP PHARMA ULC | MARKETED | 02231493 |
2 · Same class — other molecules in ATC S01EE
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Latanoprost | AG-LATANOPROST · APO-LATANOPROST · BL LATANOPROST · JAMP LATANOPROST · LATANOPROST · LATANOPROST OPHTHALMIC SOLUTION · M-LATANOPROST · MED-LATANOPROST · MINT-LATANOPROST · MONOPROST · MYLAN-LATANOPROST · PMS-LATANOPROST · RIVA-LATANOPROST · SANDOZ LATANOPROST · TARO-LATANOPROST · TEVA-LATANOPROST · XALATAN | 19 | 10 | Yes |
| Travoprost | APO-TRAVOPROST · APO-TRAVOPROST Z · IZBA · JAMP TRAVOPROST Z · MYLAN-TRAVOPROST Z · PMS-TRAVOPROST Z · SANDOZ TRAVOPROST · TEVA-TRAVOPROST Z OPHTHALMIC SOLUTION · TRAVATAN · TRAVATAN Z | 10 | 4 | Yes |
| Bimatoprost | APO-BIMATOPROST · LATISSE · LUMIGAN · LUMIGAN PF · LUMIGAN RC · VISTITAN · ZIMED PF | 8 | 4 | Yes |
| Latanoprostene Bunod | VYZULTA | 1 | 1 | Yes |
| Tafluprost | SAFLUTAN | 1 | 0 | Not in Canada |
| Unoprostone | RESCULA | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC S01E
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| S01ED | Betaxolol · Betaxolol, Combinations · Levobunolol · Levobunolol, Combinations · Timolol · Timolol, Combinations | 107 | 28 |
| S01EA | Apraclonidine · Brimonidine · Dipivefrine · Epinephrine | 28 | 10 |
| S01EC | Acetazolamide · Brinzolamide · Brinzolamide, Combinations · Dorzolamide · Methazolamide | 32 | 8 |
| S01EB | Acetylcholine · Carbachol · Ecothiopate · Pilocarpine · Pilocarpine, Combinations | 65 | 4 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is BL LATANOPROST called?
The same molecule, Latanoprost, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Monoprost | Latin | Norway, Sweden |
| Xalatan | Latin | Australia, Bahrain, Czechia, Morocco, Norway, Slovakia |
| Roclanda | Latin | Norway, Saudi Arabia |
| Xalacom | Latin | Australia, Bahrain, South Africa |
| Catiolanze | Latin | Bahrain, Czechia, Norway |
| APO-Latanoprost | Latin | Australia |
| Latanoprost Sandoz | Latin | Australia |
| Latanoprost STADA | Latin | Czechia, Sweden |
| MONOPOST | Latin | Czechia |
| Xalaprost | Latin | Australia |
| Xatamont | Latin | Norway, Sweden |
| AKISTAN | Latin | Czechia |
| Fixopost | Latin | Norway |
| Latanoprost Actavis | Latin | Sweden |
| LATANOPROST OLIKLA | Latin | Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled pre market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.